论文部分内容阅读
2015年全球销售额增长最快的前50种药物合计比去年增长410亿美元。仅吉利德(Gilead)的丙肝药物Harvoni带来的增长额就高达117亿美元,占总增长额的29%。销售增长额超过10亿美元的药物共有8个(表1),其中有3个为丙肝药物,均于2014年上市。增长最快的前10个药物合计增长额为230亿美元,相当于总增长额的56%。艾伯维(AbbV ie)的修美乐(Humira)和辉瑞(Pfizer)的沛儿(Prevnar)同时位列2015年销售额增长最快药物前10榜单和2015年最畅销药物前10榜单中,新基医药(Celgene)的Revlimid未能进入销售增速十强。
The top 50 fastest-growing global sales in 2015 combined totaled $ 41 billion more than last year. Harvoni, the Hepatitis C drug that is only Gilead, has risen as much as 11.7 billion U.S. dollars, or 29% of the total. A total of 8 drugs (Table 1) with sales exceeding US $ 1 billion were manufactured, of which three were hepatitis C drugs, both of which were listed in 2014. The top 10 fastest-growing drugs combined accounted for a total increase of $ 23 billion, equivalent to 56% of the total growth. AbbVie’s Humira and Pfizer’s Prevnar are among the top 10 fastest growing drugs in 2015 and top 10 best seller in 2015 Revlimid of Celgene failed to enter the top 10 sales growth.